604 related articles for article (PubMed ID: 26738472)
1. Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy.
Gross G; Eshhar Z
Annu Rev Pharmacol Toxicol; 2016; 56():59-83. PubMed ID: 26738472
[TBL] [Abstract][Full Text] [Related]
2. Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes.
Shirasu N; Kuroki M
Anticancer Res; 2012 Jun; 32(6):2377-83. PubMed ID: 22641678
[TBL] [Abstract][Full Text] [Related]
3. CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe.
Gilham DE; Debets R; Pule M; Hawkins RE; Abken H
Trends Mol Med; 2012 Jul; 18(7):377-84. PubMed ID: 22613370
[TBL] [Abstract][Full Text] [Related]
4. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
[TBL] [Abstract][Full Text] [Related]
5. Adoptive T-cell therapy of B-cell malignancies: conventional and physiological chimeric antigen receptors.
Liu L; Sun M; Wang Z
Cancer Lett; 2012 Mar; 316(1):1-5. PubMed ID: 22099879
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
Marcus A; Eshhar Z
Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
[TBL] [Abstract][Full Text] [Related]
7. CAR T-cell Therapy: A New Era in Cancer Immunotherapy.
Miliotou AN; Papadopoulou LC
Curr Pharm Biotechnol; 2018; 19(1):5-18. PubMed ID: 29667553
[TBL] [Abstract][Full Text] [Related]
8. Logic-gated approaches to extend the utility of chimeric antigen receptor T-cell technology.
Ebert LM; Yu W; Gargett T; Brown MP
Biochem Soc Trans; 2018 Apr; 46(2):391-401. PubMed ID: 29540509
[TBL] [Abstract][Full Text] [Related]
9. Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency.
Wang W; Ma Y; Li J; Shi HS; Wang LQ; Guo FC; Zhang J; Li D; Mo BH; Wen F; Liu T; Liu YT; Wang YS; Wei YQ
Gene Ther; 2013 Oct; 20(10):970-8. PubMed ID: 23636245
[TBL] [Abstract][Full Text] [Related]
10. Masked Chimeric Antigen Receptor for Tumor-Specific Activation.
Han X; Bryson PD; Zhao Y; Cinay GE; Li S; Guo Y; Siriwon N; Wang P
Mol Ther; 2017 Jan; 25(1):274-284. PubMed ID: 28129121
[TBL] [Abstract][Full Text] [Related]
11. CAR-modified T-cell therapy for cancer: an updated review.
Haji-Fatahaliha M; Hosseini M; Akbarian A; Sadreddini S; Jadidi-Niaragh F; Yousefi M
Artif Cells Nanomed Biotechnol; 2016 Sep; 44(6):1339-49. PubMed ID: 26068778
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor T cells: a novel therapy for solid tumors.
Yu S; Li A; Liu Q; Li T; Yuan X; Han X; Wu K
J Hematol Oncol; 2017 Mar; 10(1):78. PubMed ID: 28356156
[TBL] [Abstract][Full Text] [Related]
13. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
Maus MV; Levine BL
Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942
[TBL] [Abstract][Full Text] [Related]
14. Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.
Walker AJ; Majzner RG; Zhang L; Wanhainen K; Long AH; Nguyen SM; Lopomo P; Vigny M; Fry TJ; Orentas RJ; Mackall CL
Mol Ther; 2017 Sep; 25(9):2189-2201. PubMed ID: 28676342
[TBL] [Abstract][Full Text] [Related]
15. Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics.
Kim MG; Kim D; Suh SK; Park Z; Choi MJ; Oh YK
Arch Pharm Res; 2016 Apr; 39(4):437-452. PubMed ID: 26895243
[TBL] [Abstract][Full Text] [Related]
16. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
Di S; Li Z
Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions.
Curran KJ; Pegram HJ; Brentjens RJ
J Gene Med; 2012 Jun; 14(6):405-15. PubMed ID: 22262649
[TBL] [Abstract][Full Text] [Related]
18. Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma.
Weibo P; Zhaoming Y
Med Hypotheses; 2012 May; 78(5):616-8. PubMed ID: 22330890
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of CAR T-cell therapy in large tumors relies upon stromal targeting by IFNγ.
Textor A; Listopad JJ; Wührmann LL; Perez C; Kruschinski A; Chmielewski M; Abken H; Blankenstein T; Charo J
Cancer Res; 2014 Dec; 74(23):6796-805. PubMed ID: 25297631
[TBL] [Abstract][Full Text] [Related]
20. Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.
Jensen MC; Riddell SR
Immunol Rev; 2014 Jan; 257(1):127-44. PubMed ID: 24329794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]